Reply to comment "Comment on Jugun et al.: The safety and efficacy of high-dose daptomycin combined with rifampicin for the treatment of Gram-positive osteoarticular infections” by Lu et al by Uçkay, Ilker & Hoffmeyer, Pierre
LETTER TO THE EDITOR
Ilker Uçkay & Pierre Hoffmeyer
Received: 8 September 2013 /Accepted: 9 September 2013 /Published online: 9 October 2013
# Springer-Verlag Berlin Heidelberg 2013
Dear Prof. Pecina,
We thank you for the opportunity to answer the letter
commenting on our published article entitled “The safety and
efficacy of high-dose daptomycin combined with rifampicin
for the treatment of Gram-positive osteoarticular infections”.
The colleagues Lu, Zha and Wang have read our paper and
highlight some remarks (or opinions as they call it), which we
find pertinent and answer them with pleasure.
1. We are aware of the small sample size of 16 patients and
this is acknowledged in the manuscript [1]. This is not new.
However, Lu and colleagues need to bear in mind that our
study addressed the question of the clinical feasibility and
tolerance of high-dose daptomycin (8 mg/kg/day) com-
bined with rifampicin, another drug used in orthopaedic
surgery with a potentially important side-effect profile. As
a general principle, studies targeting the outcome of inter-
ventions usually need sample sizes beyond 50 cases in
each randomisation arm, as Lu and colleagues correctly
remark. These are usually phase III trials or other investi-
gations regarding cure or failure rates.
In contrast, tolerability studies in humans, e.g. many phase II
trials, are appropriate with a much lower sample size and
may be performedwithin a single centre such as in our study.
Therefore, it is not surprising that the local Institutional
Review Board and Swissmedic (The Swiss “FDA”)
approved our small sample size.
2. Lu et al. ask why we chose daptomycin 8 mg/kg/day
combined with rifampicin. Although we explained this
in the publication, two reasons predominated. First, dap-
tomycin is under evaluation worldwide for higher doses
than the usual 6 mg/kg/day for all types of infections.
Theoretical concerns discourage using higher doses, even
when a higher dosage could have advantages. Thus, we
chose 8 mg as a first step for the investigation. A submis-
sion involving a higher jump, e.g. directly from 6 mg/kg
to 10mg/kg, was likely to have been rejected by the Swiss
Federal authorities. Second, a combination with rifampi-
cin (or rifampin) is a well-established standard antibiotic
regimen for staphylococcal implant infections, the hall-
mark of orthopaedic infections.
3. Lu et al. regretted the absence of clinical functional recov-
ery data post infection treatment. They would have been
correct if the main investigation of our study had been the
Therapeutical approach. In our article, we concentrated on
the tolerability and safety of a particularly promising anti-
biotic combination at high doses. Such a manuscript would
have been complicated and too long if we had added
functional outcomes. Antimicrobial drugs have a range of
adverse events, including fatal ones. In most cases howev-
er, adverse events usually subside within a fewweeks, with
absence of long-term sequelae. None of our study patients
had antibiotic therapy related sequelae, and any functional
impairment depended on the anatomical and orthopaedic
conditions predating their infection.
We thank again Lu et al. for their thorough reading of our
article and their collegial remarks. We remain open for further
questions.
Yours most sincerely,
I. Uçkay, MD, and Prof. P. Hoffmeyer, MD
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